This represented 62% of total health spending in the U.S., but 49% in comparable countries. Meanwhile, prescription drugs and medical goods account for just 13% of spending in the U.S., and 16% in comparable countries.
But many comparable countries have drug price controls—which, as we know, harm patient access to lifesaving treatments. For example, of 30 new anti-infection and anti-viral medications identified in 2011-2017, 90% were available in the United States compared to 80% in Germany, 60% in France, and 57% in Canada.
More on the Peterson/Kaiser data here.
We continue to fight drug price controls and stand up for patients. We will continue to work hard to advance systemic and bipartisan reforms that address legitimate concerns about U.S. health insurance and delivery, including the affordability and accessibility of medicines.
More Health Care News:
MSNBC: Speed of vaccine development is due to ‘excellent science,’ not political pressure
“Dr. Michelle McMurry-Heath, president of trade group Biotechnology Innovation Organization and a former FDA official, calls the White House's politicization of science during the pandemic ‘unprecedented and unconscionable.’”
The New York Times: White House blocks new coronavirus vaccine guidelines
“A main sticking point has been the recommendation that volunteers who have participated in vaccine clinical trials be followed for a median of two months after the final dose before any authorization is granted.”